长春瑞宾联合顺铂治疗晚期非小细胞肺癌的临床观察

目的观察长春瑞宾联合顺铂治疗晚期非小细胞肺癌（NSCLC）的疗效及毒副作用。方法45例晚期NSCLC接受长春瑞宾和顺铂方案化疗，其中，男性31例，女性14例；腺癌27例，Ⅲ期25例，Ⅳ期20例；初治25例，复治20例。结果21例获得部分缓解（PR），17例稳定（sD），7例进展（PD），总体有效率为47％。主要毒性反应为骨髓抑制，总体白细胞减少症发生率89％，Ⅲ～IV度为20％；局部静脉炎发生率51％。结论长春瑞宾联合顺铂治疗晚期NSCLC是可行的，有效，毒副反应较低。

Vinorelbine plus cisplatin in patients with advanced non-small cell lung cancer

Objectives To evaluate the efficacy and safety of vinorelbine plus cisplatin in the management of non-small cell lung cancer （NSCLC）. Methods From May 2001 to Feb 2003, 45 patients with advanced NSCLC were enrolled in this study. The median age of the patients was 62 years. Adenocarciuoma was the most common histological type. Twenty-five patients presented with stage Ⅲ disease and 20 with stage IV. Twenty-five patients were chemo-naive and another 20 received previous chemotherapy. Results Partial response was observed in 21 patients with an overall response rate of 47%. The most common toxicity was neutropenia with grade 3/4 seen in 20% of patients. The local venous toxicity was observed in 51% of the patients. Conclusions Vinorelbine plus cisplatin are effective in advanced NSCLC.